Egypt Atherosclerosis Therapeutics Market Analysis

Egypt Atherosclerosis Therapeutics Market Executive Summary

Egypt Atherosclerosis Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $14 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period.

Atherosclerosis causes plaque, a viscous material made up of calcium, fat, cholesterol, and other substances, to build up inside the walls of arteries. This accumulation increases the chance of major illnesses, including strokes and heart attacks, which can narrow or obstruct blood vessels. Numerous variables, such as high blood pressure, high cholesterol, diabetes, obesity, smoking, a family history of heart disease, a sedentary lifestyle, and an unhealthy diet, can cause atherosclerosis. Numerous drugs, including statins, aspirin, and beta-blockers, have shown potential in slowing or stopping the development of atherosclerosis.

The prevalence of atherosclerosis risk factors, such as diabetes, obesity, dyslipidemia, and hypertension, is high in Egypt and accounts for a worrying 51% of cases of premature acute coronary syndrome, highlighting the importance of these conditions. Remarkably, there is a strong age-related association with atherosclerosis, with a prevalence of 65.8% in those over 70. Premature acute coronary syndrome is rather common (51%), with a higher prevalence in men. Among female patients, 92% were post-menopausal, emphasizing the impact of hormonal changes on cardiovascular health. The most common risk factors were found to be smoking, hypertension, and abdominal obesity; conventional risk factors, which do not include smoking, were shown to be more common in women than in males.

Recently, Egypt approved the use of Incloran (lorcaserin), a novel inhibitor of cholesterol absorption, to treat people with hyperlipidemia (high cholesterol) who are taking statins but have not achieved adequate control over their cholesterol. With the launch of Incloran, patients in Egypt who are struggling to regulate their cholesterol levels while on statins now have far more therapy alternatives at their disposal. Research has indicated that Incloran is effective in lowering low-density lipoprotein (LDL) cholesterol, also known as the "bad" cholesterol, and raising high-density lipoprotein (HDL) cholesterol, also known as the "good" cholesterol. This approval provides a novel approach to managing hyperlipidemia in the Egyptian population and addressing issues related to cholesterol.

Market Dynamics

Market Growth Drivers

Ageing population: Egypt's aging population consequently raises the risk of developing atherosclerosis due to age-related artery stiffness and plaque buildup. Egypt's elderly population, defined as those 60 years of age and older, is expected to increase significantly from 8.4 million in 2020 to 22 million by 2050. This change in population is an almost threefold rise in just three decades. An increasing number of senior people is one of the main demographic shifts driving Egypt's market for atherosclerosis medication treatments. Effective treatment options are in greater demand due to the increasing prevalence of age-related variables that contribute to atherosclerosis. The need for advanced and targeted therapies is highlighted by the expected increase in the older population, which presents a significant opportunity for the expansion of the atherosclerosis drug treatment market in Egypt.

Improved Diagnosis and Awareness: Expanded access to diagnostic tools like angiography and ultrasonography, facilitated by public-private sector funding and government initiatives, is driving early detection and treatment initiation in Egypt. Increased investments in healthcare infrastructure and effective public awareness campaigns are key factors fuelling the growth of the atherosclerosis drug treatment market. The availability of advanced diagnostic technologies enhances early detection, while heightened public awareness stimulates demand for both preventive measures and treatments, contributing to market expansion.

Advancements in Drug Development: In response to the increasing number of patients and diverse requirements, pharmaceutical companies are anticipated to intensify their ongoing endeavours in creating innovative atherosclerosis drugs, customized to different pathways and patient needs. This concerted effort is poised to expedite the expansion of the market in Egypt.

Market Restraints

Affordability and Access: A significant portion of the population, especially those with lower incomes, may find it difficult to obtain newly developed treatments like PCSK9 inhibitors and CETP inhibitors due to their exorbitant costs. The high cost of innovative medicines poses a financial barrier, which in turn restrains the market for atherosclerosis therapy drugs in Egypt. The pricing dynamics create challenges for individuals, particularly those with limited financial resources, restricting their access to these advanced medications. Incomplete insurance coverage for some expensive medications further exacerbates the affordability issue and limits the market's potential expansion, even in Egypt, a country with a strong healthcare system.

Healthcare infrastructure limitations: Inequitable access to medical care, especially in remote locations, may make it more difficult to identify and treat atherosclerosis promptly. Delays may arise from a lack of knowledge about risk factors and budgetary limitations brought on by insufficient insurance coverage for long-term illnesses like atherosclerosis. These issues with Egypt's healthcare system have an impact on patient knowledge, accessibility, and financial support. As a result, they hinder the efficient management of atherosclerosis and limit the market for atherosclerosis therapy medications in the nation.

Compliance and Adherence Issues: The prolonged use of drugs in atherosclerosis treatment poses challenges such as adverse effects, forgetfulness, and low motivation for some patients. Managing numerous prescriptions for different medical conditions makes adherence problems worse, which could limit the commercial potential of atherosclerosis treatment options because of difficulties with patient compliance.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Population (MOHP) and the Egyptian Drug Authority (EDA) are principally responsible for regulatory monitoring and healthcare policy in Egypt with regard to prescription medications. The Ministry of Health and Population holds a pivotal position in the development and execution of healthcare policies, guaranteeing the availability, cost-effectiveness, and excellence of medical services, encompassing pharmaceuticals. Under the Ministry of Health's auspices, the Egyptian Drug Authority is in charge of policing and supervising pharmaceutical product safety, quality assurance, licensing, and registration. In order to protect the public's health, these regulatory agencies' cooperation creates a strong framework that controls the creation, authorization, and distribution of therapeutic medications in Egypt.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Abbott
• Eli Lilly
• GlaxoSmithKline
• Teva Pharmaceutical
• Roche